Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [41] The role of autophagy in chemotherapy resistance of cisplatin in ovarian cancer
    Alsoulaiman, Lamak
    Biktagirova, Elnara
    Abramova, Zinaida
    CELL DEATH DISCOVERY, 2021, 7 (SUPPL 1) : 1 - 1
  • [42] Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
    Song, Mengdi
    Cui, Mingxiao
    Liu, Kehai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 232
  • [43] Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
    Wang, Juan
    Wu, Gen Sheng
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (24) : 17163 - 17173
  • [44] RON and Cisplatin Resistance in Ovarian Cancer Cell Lines
    Prislei, Silvia
    Mariani, Marisa
    Raspaglio, Giuseppina
    Mozzetti, Simona
    Filippetti, Flavia
    Ferrandina, Gabriella
    Scambia, Giovanni
    Ferlini, Cristiano
    ONCOLOGY RESEARCH, 2010, 19 (01) : 13 - 22
  • [45] Comprehensive proteomic analysis of cisplatin resistance in ovarian cancer
    Teng, Pang-ning
    Hood, Brian L.
    Litzi, Tracy
    Chappell, Nicole P.
    Hamilton, Chad A.
    Maxwell, G. Larry
    Conrads, Thomas P.
    CANCER RESEARCH, 2012, 72
  • [46] Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
    Schweer, David
    McCorkle, J. Robert
    Rohr, Jurgen
    Tsodikov, Oleg V.
    Ueland, Frederick
    Kolesar, Jill
    BIOMEDICINES, 2021, 9 (01) : 1 - 11
  • [47] Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer
    Chappell, Nicole P.
    Teng, Pang-ning
    Hood, Brian L.
    Wane, Guisong
    Darcy, Kathleen M.
    Hamilton, Chad A.
    Maxwell, G. Larry
    Conrads, Thomas P.
    JOURNAL OF PROTEOME RESEARCH, 2012, 11 (09) : 4605 - 4614
  • [48] Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
    Liu, Chengfei
    Lou, Wei
    Zhu, Yezi
    Nadiminty, Nagalakshmi
    Schwartz, Chad T.
    Evans, Christopher P.
    Gao, Allen C.
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3198 - 3210
  • [49] Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells
    Kulshrestha, Arpita
    Katara, Gajendra K.
    Ginter, Jordyn
    Pamarthy, Sahithi
    Ibrahim, Safaa A.
    Jaiswal, Mukesh K.
    Sandulescu, Corina
    Periakaruppan, Ramayee
    Dolan, James
    Gilman-Sachs, Alice
    Beaman, Kenneth D.
    MOLECULAR ONCOLOGY, 2016, 10 (06): : 789 - 805
  • [50] How Liposomal Cisplatin Overcomes Chemoresistance in Ovarian Tumour Cells
    Stoelting, Daniel Philipp
    Borrmann, Michaela
    Koch, Martin
    Wiese, Michael
    Royer, Hans-Dieter
    Bendas, Gerd
    ANTICANCER RESEARCH, 2014, 34 (1B) : 525 - 530
12345